Hong Kong Prohibits CBD Products: 7-Year Imprisonment and Heavy Fines

Jan.12.2023
Hong Kong Prohibits CBD Products: 7-Year Imprisonment and Heavy Fines
Hong Kong bans all CBD products, adding them to its Dangerous Drugs Ordinance, with the possibility of severe punishments.

Hong Kong, China recently announced that all products containing cannabidiol (CBD) will be banned starting February 1st. CBD will be added to the Dangerous Drugs Ordinance (DDO), which already includes over 200 substances such as fentanyl, ketamine, heroin, and various psychoactive compounds like MDMA.


CBD will now be included in the existing list of "cannabinol and its tetrahydro derivative (THC); as well as 3-alkyl homologues." As a result of this change, anyone who possesses or consumes CBD will face a maximum of seven years in prison and a fine of up to HKD 1 million (approximately RMB 870,000).


According to Lexology, manufacturers of CBD may also face life imprisonment.


Although many users around the world have been touting the anti-anxiety and pain-relieving properties of CBD, the Hong Kong Security Bureau believes that these claims "lack authoritative scientific evidence." This directive appears to be consistent with China's ban on the use of CBD in cosmetics implemented last year.


Currently, it is unclear whether other cannabinoids such as CBG, CBDV, CBC, etc. will be included in the ban. However, based on a memorandum from the Narcotics Division in November 2022, the Hong Kong government appears to be primarily concerned about the possibility of CBD products containing trace amounts of THC, either through breakdown or conversion, and the lack of international regulations specifically for these products.


Article Related Reading: Hong Kong plans to completely ban the sale of CBD products by the end of 2022.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI U.S. White Paper Calls for Greater Access to FDA-Authorized Smoke-Free Alternatives and Risk-Based Taxation
PMI’s U.S. business released a white paper and cited a national online survey showing that 79.00% of Americans surveyed believe more should be done to reduce smoking-related harm. The paper calls on policymakers, public health authorities, and medical professionals to place cigarette smoking back at the center of public health priorities, and recommends broader access to FDA-authorized smoke-free alternatives, clearer nicotine risk communication, and risk-based taxation.
Apr.15 by 2FIRSTS.ai
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
Turkey’s New Tobacco Bill Draft Would Cover E-Cigarettes and Heated Tobacco Products
A Turkey’s draft would impose major limits on the use of tobacco products in public buildings, educational and healthcare institutions, children’s areas, and outdoor events, while setting a 2040 target for a complete ban on the production, sale, and consumption of tobacco products. The draft also broadens the definition of tobacco products to include e-cigarettes, heated tobacco products, and all nicotine-containing systems.
Apr.13 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS Urges USTR to Address Illegal E-Cigarette Exports in China Trade Engagements
NACS submitted a comment letter to USTR in a proceeding examining unfair trade practices worldwide. The letter focuses on illicit nicotine products made in China and shipped to the United States in violation of U.S. law. NACS said the U.S. electronic nicotine delivery systems market has become dominated by illicit products, mainly disposable e-cigarettes manufactured in China and sold without the marketing authorization required by the U.S. Food and Drug Administration.
Apr.16 by 2FIRSTS.ai
Korean Vape Retailers Warn of Possible Store Closures After New Tobacco Rules Take Effect
Korean Vape Retailers Warn of Possible Store Closures After New Tobacco Rules Take Effect
South Korea’s revised Tobacco Business Act will take effect on April 24, bringing synthetic nicotine liquid vapes into the legal definition of tobacco and subjecting both retailers and manufacturers to formal regulation.
Apr.13 by 2FIRSTS.ai
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
FDA Renews Exposure Modification Authorization for IQOS Devices and Three HeatSticks Products
U.S. Food and Drug Administration renewed modified risk granted orders for five IQOS products from Philip Morris Products S.A., including two IQOS system holders and chargers and three HeatSticks products. Under the renewed orders, the products may continue to be marketed with an exposure modification claim.
Apr.20 by 2FIRSTS.ai